+

WO2009074364A1 - Nouveau marqueur pronostique du cancer du sein - Google Patents

Nouveau marqueur pronostique du cancer du sein Download PDF

Info

Publication number
WO2009074364A1
WO2009074364A1 PCT/EP2008/063062 EP2008063062W WO2009074364A1 WO 2009074364 A1 WO2009074364 A1 WO 2009074364A1 EP 2008063062 W EP2008063062 W EP 2008063062W WO 2009074364 A1 WO2009074364 A1 WO 2009074364A1
Authority
WO
WIPO (PCT)
Prior art keywords
dkk3
dna
breast
region
breast cancer
Prior art date
Application number
PCT/EP2008/063062
Other languages
English (en)
Other versions
WO2009074364A8 (fr
Inventor
Edgar Dahl
Jürgen VEECK
Original Assignee
Edgar Dahl
Veeck Juergen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Edgar Dahl, Veeck Juergen filed Critical Edgar Dahl
Publication of WO2009074364A1 publication Critical patent/WO2009074364A1/fr
Publication of WO2009074364A8 publication Critical patent/WO2009074364A8/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/154—Methylation markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Definitions

  • breast cancer Many factors contribute to the pathogenesis of breast cancer. These factors include family history, nutrition, age, and epigenetic changes including DNA methylation. About 5 to 10% of breast cancer cases are due to inherited, mutated genes (BRCAl, BRCA2). The majority (90%) of breast cancers are due to genetic abnormalities that happen as a result of the aging process and life in general.
  • the present invention further provides a method for the diagnosis and/or prognosis of breast cancer by detecting epigenetic silencing of the DKK3 gene in a test sample, wherein the epigenetic silencing indicates breast cancer or predisposition to breast cancer.
  • methylation profile or "methylation status,” when used herein to describe the state of methylation of a genomic sequence, refers to the characteristics of a DNA segment at a particular genomic locus relevant to methylation, i.e. at particular CpG dinucleotides in a CpG island. Such characteristics include, but are not limited to, whether any of the cytosine (C) residues within this DNA sequence are methylated, location of methylated C residue(s), percentage of methylated C at any particular stretch of residues, and allelic differences in methylation due to, e.g., difference in the origin of the alleles.
  • methylation profile or “methylation status” also refers to the relative or absolute concentration of methylated C or unmethylated C at any particular stretch of residues in a test sample.
  • the methylation status of the differentially methylated CpG islands can provide a variety of information about the disease of breast cancer. It can be used to diagnose breast (pre)cancer in the individual. Alternatively, it can be used to predict the course of the disease in the individual or to predict the susceptibility to the disease, or to stage the progression of the disease in the individual. Importantly, it can help to predict the likelihood of overall survival, cause-specific survival, disease-free survival, or predict the likelihood of reoccurrence of breast cancer, and determine the effectiveness of a treatment course undergone by the individual. Increase or decrease of methylation levels in comparison with a reference level, and alterations in the increased/decreased detected levels provide valuable prognostic and diagnostic information.
  • the method of selecting a suitable treatment for breast (pre)cancer involves as well the discrimination between potential drugs, in the sense that a drug selected from a DNA demethylating agent, a DNA methyltransferase inhibitor, a HDAC inhibitor, and a combination thereof, is contra-indicated for treatment if increased expression of the DKK3 gene, and/or reduced or no methylation of the DKK3 gene, of a region thereof, or of a regulatory region thereof, is detected.
  • MSP Bisulphite-modification and methylation-specific PCR

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

L'invention concerne le silençage épigénétique du gène DKK3 dans les cancers du sein, ainsi que les utilisations de ce marqueur dans le diagnostic et le pronostic du cancer du sein et dans le choix de traitements thérapeutiques appropriés.
PCT/EP2008/063062 2007-12-13 2008-09-30 Nouveau marqueur pronostique du cancer du sein WO2009074364A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1357307P 2007-12-13 2007-12-13
US61/013,573 2007-12-13

Publications (2)

Publication Number Publication Date
WO2009074364A1 true WO2009074364A1 (fr) 2009-06-18
WO2009074364A8 WO2009074364A8 (fr) 2009-08-13

Family

ID=40297929

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2008/063062 WO2009074364A1 (fr) 2007-12-13 2008-09-30 Nouveau marqueur pronostique du cancer du sein

Country Status (1)

Country Link
WO (1) WO2009074364A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3162899A1 (fr) * 2015-10-29 2017-05-03 Rheinisch-Westfälische Technische Hochschule (RWTH) Aachen Biomarqueur pour le cancer du sein
US9856301B2 (en) * 2012-03-26 2018-01-02 University Of Massachusetts Anti-tumor properties of Dickkopf 3b
WO2024216112A1 (fr) * 2023-04-12 2024-10-17 Guardant Health, Inc. Détection de méthylation du promoteur

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020183388A1 (en) * 2001-02-01 2002-12-05 Gudas Lorraine J. Use of retinoids plus histone deacetylase inhibitors to inhibit the growth of solid tumors
WO2005027712A2 (fr) * 2003-05-30 2005-03-31 Temple University - Of The Commonwealth System Of Higher Education Methodes de diagnostic, pronostic et de traitement du cancer du sein
WO2005111232A2 (fr) * 2004-05-17 2005-11-24 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Extinction de genes supresseurs de tumeur par methylation cpg dans un cancer de la prostate
WO2006008128A2 (fr) * 2004-07-18 2006-01-26 Epigenomics Ag Methodes epigenetiques et acides nucleiques permettant de deceler des troubles proliferatifs des cellules du sein

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020183388A1 (en) * 2001-02-01 2002-12-05 Gudas Lorraine J. Use of retinoids plus histone deacetylase inhibitors to inhibit the growth of solid tumors
WO2005027712A2 (fr) * 2003-05-30 2005-03-31 Temple University - Of The Commonwealth System Of Higher Education Methodes de diagnostic, pronostic et de traitement du cancer du sein
WO2005111232A2 (fr) * 2004-05-17 2005-11-24 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Extinction de genes supresseurs de tumeur par methylation cpg dans un cancer de la prostate
WO2006008128A2 (fr) * 2004-07-18 2006-01-26 Epigenomics Ag Methodes epigenetiques et acides nucleiques permettant de deceler des troubles proliferatifs des cellules du sein

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE Geneseq [online] 23 March 2006 (2006-03-23), "Human genomic DNA #24.", XP002515110, retrieved from EBI accession no. GSN:AEF55043 Database accession no. AEF55043 *
VEECK JÜRGEN ET AL: "Wnt signalling in human breast cancer: expression of the putative Wnt inhibitor Dickkopf-3 (DKK3) is frequently suppressed by promoter hypermethylation in mammary tumours.", BREAST CANCER RESEARCH : BCR 2008, vol. 10, no. 5, 30 September 2008 (2008-09-30), pages R82, XP002515109, ISSN: 1465-542X *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9856301B2 (en) * 2012-03-26 2018-01-02 University Of Massachusetts Anti-tumor properties of Dickkopf 3b
US11421008B2 (en) 2012-03-26 2022-08-23 University Of Massachusetts Anti-tumor properties of Dickkopf 3b
EP3162899A1 (fr) * 2015-10-29 2017-05-03 Rheinisch-Westfälische Technische Hochschule (RWTH) Aachen Biomarqueur pour le cancer du sein
WO2017072292A1 (fr) * 2015-10-29 2017-05-04 Rheinisch-Westfälische Technische Hochschule (Rwth) Aachen Biomarqueur pour le cancer du sein
WO2024216112A1 (fr) * 2023-04-12 2024-10-17 Guardant Health, Inc. Détection de méthylation du promoteur

Also Published As

Publication number Publication date
WO2009074364A8 (fr) 2009-08-13

Similar Documents

Publication Publication Date Title
US10113202B2 (en) Method for determining the methylation status of the promoter region of the TWIST1 gene in genomic DNA from bladder cells
JP6141896B2 (ja) 選択された遺伝子のエピジェネティックな変化及び癌
US20170121775A1 (en) Detection and Prognosis of Lung Cancer
US20150086989A1 (en) Methods and nucleic acids for analyses of cellular proliferative disorders
US20150072947A1 (en) Gene biomarkers for prediction of susceptibility of ovarian neoplasms and/or prognosis or malignancy of ovarian cancers
US9096905B2 (en) Detecting DNA methylation of BCL2, CDKN2A and NID2 genes to predict bladder cancer in humans
WO2007140319A1 (fr) Promoteurs méthylés utilisés en tant que biomarqueurs du cancer du côlon
US20210404018A1 (en) Unbiased dna methylation markers define an extensive field defect in histologically normal prostate tissues associated with prostate cancer: new biomarkers for men with prostate cancer
Xu et al. SAMD14 promoter methylation is strongly associated with gene expression and poor prognosis in gastric cancer
WO2013064163A1 (fr) Marqueurs de méthylation pour le cancer colorectal
CN112041463B (zh) 结肠直肠癌的miRNA标志物
WO2009074364A1 (fr) Nouveau marqueur pronostique du cancer du sein
JP2022536846A (ja) 胃癌を診断するための高メチル化遺伝子の検出
US9388471B2 (en) Methylation of the GATA4 gene in urine samples as a marker for bladder cancer detection
CA2904126C (fr) Marqueurs moleculaires dans le cancer de la vessie
CN116622842A (zh) 一种用于肺腺癌非创早期诊断、药效评估的分子标志物及试剂盒
Kwan Epigenetic Study of Plasma Circulating DNA in Prostate Cancer
Ferreira Epigenetic Study of Colorectal Cancer: lncRNAs and CIMP Profiling
Dvořáková Molekulářně biologické změny u karcinomu endometria

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08860661

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08860661

Country of ref document: EP

Kind code of ref document: A1

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载